SBRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sabra Health Care REIT Inc (SBRA) is not a strong buy at this moment for a beginner investor with a long-term focus. While the technical indicators show bullish trends, the financial performance has been weak, with significant drops in net income, EPS, and gross margin. Additionally, there are no significant positive catalysts or recent news to justify immediate action. Analysts have mixed ratings, and the options data suggests a lack of strong bullish sentiment. Holding the stock or waiting for a clearer entry point may be a better strategy.
The technical indicators show bullish trends with MACD positively expanding, RSI in the neutral zone, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The stock is currently trading near its resistance level of 20.608, with support at 19.649.
Analysts have raised price targets recently, with some maintaining Buy ratings. The senior housing sector is viewed positively within the REIT space, and there is potential for same-store net operating income growth in 2026.
The company's Q4 financials showed a significant drop in net income (-41.70% YoY), EPS (-42.11% YoY), and gross margin (-8.17% YoY). There are no recent news updates or significant trading trends from hedge funds, insiders, or Congress. Options data indicates low bullish sentiment.
In Q4 2025, revenue increased by 16.21% YoY to $211.9M, but net income dropped by 41.70% YoY to $27.2M. EPS fell by 42.11% YoY to 0.11, and gross margin declined by 8.17% YoY to 63.75.
Analysts have mixed ratings. Some firms like Citi and BofA maintain Buy ratings with price targets of $24 and $23, respectively. Others, like Truist and Scotiabank, maintain Hold or Neutral ratings with price targets around $21-$22. Analysts are cautiously optimistic about the senior housing sector but remain cautious about near-term challenges in skilled nursing facilities.
